The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy

Brown, Vivienne; Sitzia, John; Richardson, Alison; Hughes, Jayne; Hannon, Helen; Oakley, Clare

doi:10.1016/s0020-7489(00)00106-1

Cited by 54 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study demonstrates that the ASyMS Questionnaire not returned: n=2 (28) 23 (20) 8 (7) 6 (5) 5 (5) 8 (7) 3 (3) 4 (4) 23 (21) 15 (27) 12 (21) 5 (9) 3 (5) 2 (4) 4 (7) 2 (2) 3 (5) 10 (16) 17 (30) 11 (20) 3 (5) 3 (5) 3 (5) 4 (7) 1 (2) 1 (2) 13 (25) ** The average proportion of subjects with the attribute over the 4 post randomisation cycles. …”

Section: Discussionmentioning

confidence: 99%

“…The use of mobile technology appears to be well suited to the remote monitoring of chemotherapy related toxicity due to the high prevalence of out-patient care and the availability and accessibility of standardised methods of symptom assessment which are commonly used within clinical practice [25][26] . The system reported here is a mobile phone based, remote monitoring, advanced symptom management system (ASyMS © ) which has been developed over a period of 5 years to remotely monitor and manage chemotherapy related toxicity in patients with cancer 22,27 .…”

Section: Contributory Factors Include Poor Communication Between Patimentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity

Kearney

McCann

Norrie

et al. 2008

Support Care Cancer

255

247

View full text Add to dashboard Cite

ABSTRACT:Objectives: To evaluate the impact of a mobile phone based, remote monitoring, advanced symptom management system (ASyMS © ) on the incidence, severity and distress of six chemotherapy related symptoms (nausea, vomiting, fatigue, mucositis, hand foot syndrome, diarrhoea) in patients with lung, breast or colorectal cancer. Main outcome measures:Chemotherapy related morbidity of six common chemotherapy related symptoms (nausea, vomiting, fatigue, mucositis, hand foot syndrome and diarhhoea)Results: There were significantly higher reports of fatigue in the control group compared to the intervention group (odds ratio 2.29, 95% CI 1.04 to 5.05, P=0.040) and reports of hand foot syndrome were on average lower in the control group (odds ratio control: intervention, 0.39, 95% CI to 0.92, P=0.031).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Contributory Factors Include Poor Communication Between Patimentioning

confidence: 99%

Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity

Kearney

McCann

Norrie

et al. 2008

Support Care Cancer

255

247

View full text Add to dashboard Cite

show abstract

“…We identified possible ADEs from the Common Terminology Criteria for Adverse Events version 4.0 [22], and existing symptom and ADE checklists [3,13,18,[23][24][25][26][27][28][29]. Patient-reported data about ADEs from the Lareb Intensive Monitoring System of The Netherlands Pharmacovigilance Centre Lareb [30] were used to translate ADEs into lay-terms.…”

Section: Adverse Drug Event (Ade) Selection and Naming In Lay-termsmentioning

confidence: 99%

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire

et al. 2013

View full text Add to dashboard Cite

Background Direct patient reporting of adverse drug events (ADEs) is relevant for the evaluation of drug safety. To collect such data in clinical trials and postmarketing studies, a valid questionnaire is needed that can measure all possible ADEs experienced by patients. Objective Our aim was to develop and test a generic questionnaire to identify ADEs and quantify their nature and causality as reported by patients. Methods We created a draft list of common ADEs in layterms, which were classified in body categories and mapped to the Medical Dictionary for Regulatory Activities (MedDRA Ò ) terminology. Questions about the nature and causality were derived from existing questionnaires and causality scales. Content validity was tested through cognitive debriefing, revising the questionnaire in an iterative process. Feasibility and reliability were assessed using a Web-based version of the questionnaire. Patients received the questionnaire twice. Feasibility was assessed by the reported time needed for completion and ease of use. Reliability was calculated using Cohen's kappa and proportion of positive agreement (PPA) on: (1) any ADE at patient level; (2) similar ADEs at MedDRA Ò System Organ Class level; and (3) the same ADE at ADE-specific level.Results In the development phase, 28 patients with type 2 diabetes or asthma/chronic obstructive pulmonary disease (COPD) participated. Questions and answer options were rephrased, layout was improved, and changes were made in the classification of ADEs. The final questionnaire consisted of 252 ADEs organized in 16 body categories, and included 14 questions per reported ADE. A total of 135 patients using a median of five different drugs completed the Web-based questionnaire twice. The median completion time was 15 min for patients not reporting any ADE, and 30 min for patients reporting at least one ADE. Three quarters of the patients found the questionnaire easy to use. Test-retest reliability was acceptable at patient level (j = 0.50, PPA 0.64) and at MedDRA Ò System Organ Class level (j = 0.52, PPA 0.54), but was low at ADEspecific level (j = 0.38, PPA 0.38). Conclusion We developed a generic patient-reported ADE questionnaire and confirmed its content validity. The questionnaire was feasible and reliable for reporting any ADE and similar ADEs at MedDRA Ò System Organ Class level. Additional work is, however, needed to reliably quantify specific ADEs reported by patients.

show abstract

“…Patients need to describe their effect to the health care professionals involved in their treatment and management. Using reliable and valid assessment tools can help patients to verbalize and clarify their symptom experience into a more objective form, which can then be measured (14).…”

Section: Discussionmentioning

confidence: 99%

Psychometric Development of Chemotherapy Side Effects Fear Scale

Vasić¹,

Janković²,

Jelić³

2017

Acta Facultatis Medicae Naissensis

View full text Add to dashboard Cite

SU M M A RYAnxiety, depression and fear in general are the most common emotional problems in people with cancer and it is necessary to recognize them. The patients' attitude towards the side effects of chemotherapy has changed significantly in recent years and psychological effects, rather than physiological ones, are becoming increasingly important.The aim of this study was to develop and validate a reliable questionnaire that can measure cancer patients' fear of the chemotherapy side effects (CheSeFS).A CheSeFS is a unique, reliable and valid two-factor 14-item instrument, a clinically useful tool to assess fear of the chemotherapy side effects in cancer patients.

show abstract

The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy

Cited by 54 publications

References 17 publications

Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity

Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire

Psychometric Development of Chemotherapy Side Effects Fear Scale

Contact Info

Product

Resources

About